Table 2.
Comparison |
Before matching |
After matching |
||||
---|---|---|---|---|---|---|
HR | 95% CI | P-Value | HR | 95% CI | P-Value | |
Progression-free survival |
|
|
|
|
|
|
Everolimus vs. Placebo |
0.38 |
0.29-0.49 |
<0.001 |
0.35 |
0.24-0.52 |
<0.001 |
Sunitinib vs. Placebo |
0.42 |
0.26-0.66 |
<0.001 |
0.42 |
0.26-0.66 |
<0.001 |
Everolimus vs. Sunitiniba |
0.90 |
0.53-1.53 |
0.695 |
0.84 |
0.46-1.53 |
0.578 |
Overall survival |
|
|
|
|
|
|
Everolimus vs. Placebo in A6181111 |
0.53 |
0.35-0.78 |
0.002 |
0.61 |
0.38-0.98 |
0.042 |
Everolimus vs. Sunitinib | 0.69 | 0.46-1.05 | 0.087 | 0.81 | 0.49-1.31 | 0.383 |
Notes:
aComparison based on the HR for everolimus vs. placebo divided by the HR for sunitinib vs. placebo.